Oral · GLP-1 / amylin
Amycretin / zenagamtide
21 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
21
Active
12
Recruiting
9
Completed
9
Sites
1,279
Countries
34
Endpoints
368
Composite endpoints
4
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
10
Phase 2
2
Phase 3
9
Trials by status
Not yet recruiting
3
Recruiting
9
Completed
9
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
96
Cardiometabolic biomarkers
88
Weight & body composition
50
Other clinical outcomes
49
Glycemic / diabetes
47
Patient-reported / QoL
22
Renal / kidney
6
Other (unclassified)
5
Cardiovascular outcomes
3
Heart failure
2
Most-measured metrics
Top 20 metrics across this asset's endpoints
Treatment-emergent AEs (any)Safety/PK
19
AUC₀–∞Safety/PK
18
Body weight, % changeWeight
18
CmaxSafety/PK
16
Fasting glucose, changeGlycemic
14
OSA responderOther clin.
13
Systolic BP, changeBiomarker
11
Waist circumference, changeWeight
10
Body weight, absolute change (kg)Weight
10
BMI, changeWeight
10
Total cholesterol, changeBiomarker
10
HDL-C, changeBiomarker
10
LDL-C, changeBiomarker
10
Triglycerides, changeBiomarker
10
hs-CRP, changeBiomarker
10
HbA1c, changeGlycemic
10
Diastolic BP, changeBiomarker
9
VLDL, changeBiomarker
9
Non-HDL cholesterol, changeBiomarker
9
Serious AEs (any)Safety/PK
9
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
21 of 21